 |
The Gilead Debate:this house believes there is still a role for empirical antifungal therapy
Rosemary Barnes(UK)
Duration:07:36
Session:Integrated symposium 4 - sponsored by Gilead
|
|
 |
The Gilead Debate:this house believes there is still a role for empirical antifungal therapy
Nicole Blijlevens(The Netherlands)
Duration:04:39
Session:Integrated symposium 4 - sponsored by Gilead
|
|
 |
Role of molecular methods in diagnosis
Stephane Bretagne(France)
Duration:30:20
Session:Workshop 6:Molecular mycology/taxonomy
|
|
 |
Genome-wide responses of Candida albicans to host stimuli
Al Brown(UK)
Duration:21:42
Session:Workshop 3:Large scale analysis in the host - pathogen interaction
|
|
 |
Therapeutic drug monitoring in antifungal therapy: why, when, how?
Roger Bruggemann(The Netherlands)
Duration:19:00
Session:Workshop 1:Diagnostic issues for clinicians
|
|
 |
mAbs to fungal species
James Burnie(UK)
Duration:21:47
Session:Workshop 16:Preventing and treating IFI: What’s on the horizon?
|
|
 |
IDSA Candidiasis Guidelines:The Case for Initiating therapy with Enchinocandins Versus Fluconazole in High Risk Patients
Thierry Calandra(Switzerland)
Duration:19:24
Session:Integrated symposium 1 - sponsored by Merck Sharp & Dohme
|
|
 |
Fungal infections in LTX and CF
Elio Castagnola(Italy)
Duration:20:09
Session:Workshop 2:Lungs as target of fungi and treatment
|
|
 |
ECIL vs IDSA guidelines.Trends in the management of invasive fungal infections
Catherine Cordonnier(France)
Duration:13:28
Session:Plenary session 5:Transatlantic viewpoints (us and them)
|
|
 |
In the Haematological population
Oliver Cornely (Germany)
Duration:24:51
Session:Workshop 12:Iatrogenic risk factors in the non - neutropenic patient
|
|
 |
Radiolabeled antibodies in the treatment of fungal infections
Ekaterina Dadachova(USA)
Duration:22:53
Session:Workshop 16: Preventing and treating IFI: What’s on the horizon?
|
|
 |
Immunosuppression in patients with non-malignant diseases
George Daikos(Greece)
Duration:24:45
Session:Workshop 12: Iatrogenic risk factors in the non - neutropenic patient
|
|
 |
Aspergillus
David Denning (UK)
Duration:16:16
Session:Plenary session 1: Epidemiology: Do we know who gets what, why and when?
|
|
 |
Fungal asthma
David Denning(UK)
Duration:37:05
Session:Plenary session 3: Fungi related allergic syndromes
|
|
 |
Introduction-Implementing Antifungal Prophylaxis Into Clinical Practice
Rafael F.Duarte(Spain)
Duration:35:22
Session:Integrated symposium 1 - sponsored by Merck Sharp & Dohme
|
|
 |
Panel Discussion & Concluding Comments
Rafael F. Duarte(Spain)
Duration:06:38
Session:Integrated symposium 3 - sponsored by Schering - Plough
|
|
 |
African histoplasmosis
Bertrand Dupont(France)
Duration:20:20
Session:Workshop 7: Travel and immigration related mycosis
|
|
 |
What is the role of LAF in preventing IFI?
Petra Gastmeier(Germany)
Duration:19:13
Session:Workshop 10: Environmental mycology
|
|
 |
Foreign bodies and biofilms
Mahmout Ghannoum(USA)
Duration:19:43
Session:Workshop 12: Iatrogenic risk factors in the non - neutropenic patient
|
|
 |
EUCAST vs CLSI, Antifungal susceptibility testing
Mahmoud Ghannoum(USA)
Duration:11:12
Session:Plenary session 5: Transatlantic viewpoints (us and them)
|
|
 |
Proteomic profile during Candida infection
C.Gil(Spain)
Duration:22:39
Session:Workshop 3: Large scale analysis in the host-pathogen interaction
|
|
 |
Antifungal PK/PD in neonates and children
Andreas H. Groll(UK)
Duration:19:10
Session:Workshop 15: Invasive fungal infections in neonates and children
|
|
 |
Prevention of invasive fungal infections in solid organ transplant recipients: Universal or targeted prophylaxis?
Paolo Grossi(Italy)
Duration:19:33
Session:Workshop 5: Approaches to prophylaxis nad targeted treatment
|
|
 |
Other tropical mycoses
R.J. Hay(UK)
Duration:26:16
Session:Workshop 7: Travel and immigration related mycosis
|
|
 |
Treating fungal infections
Raoul Herbrecht(France)
Duration:25:30
Session:Workshop 13: Top ten papers: Illustrating achievements and setting new goals
|
|
 |
Imaging findings in neutropenic vs non-neutropenic patients
Claus Peter Heussel(Germany)
Duration:21:35
Session:Workshop 1: Diagnostic issues for clinicians
|
|
 |
Assess optimal PK/PD characteristics of antifungal agents
William Hope(UK)
Duration:30:57
Session:Plenary session 2: The role of PK/PD in choosing antifungal drug dosing strategies
|
|
 |
Role of molecular typing in tracking fungal outbreaks
C.Klaassen(The Netherlands)
Duration:16:54
Session:Workshop 10: Enviromental mycology
|
|
 |
Experimental pathogenesis and virulence
Dimitrios Kontoyiannis(USA)
Duration:23:14
Session:Workshop 3: Uncommon and emerging fungal pathogens
|
|
 |
Virulence of FKS resistant strains of candida and aspergillus and the implications
Dimitrios Kontoyiannis(USA)
Duration:16:45
Session:Integrated symposium 1: Sponsored by Merck Sharp and Dohme
|
|
 |
New insights into polyene resistance
C.Lass-Floerl(Austria)
Duration:16:03
Session:Workshop 11: Antifungal resistance and treatment stategies
|
|
 |
Adoptive antifungal immunotherapy
Thomas Lehrnbecher(Germany)
Duration:18:13
Session:Workshop 16: Preventing and treating IFI: What's on the horizon?
|
|
 |
Intrapulmonary drug disposition, PD Interactions of antifungal drugs with pulmonary host cells
Russell E. Lewis(USA)
Duration:16:06
Session:Workshop 2: Lungs as target of fungi and treament
|
|
 |
Options for treatment in patients
Olivier Lortholary(France)
Duration:21:41
Session:Workshop 4: Uncommon and emerging fungal pathogens
|
|
 |
Practical consideration for diagnosing and treating suspected IFD in hematological patients
Johan Maertens(Belgium)
Duration:27:51
Session:Integrated symposium 1: Sponsored by Merck Sharp and Dohme
|
|
 |
Use of polyene aerosols for prophylaxis
Johan Maertens(Belgium)
Duration:25:29
Session:Workshop 5: Approaches to prophylaxis and targeted treatment
|
|
 |
Prophylaxis, empirical, pre-emptive therapy in presumed aspergillosis in hematolological patients: Which strategy?
G. Maschmeyer(Germany)
Duration:26:25
Session:Workshop 5: Approaches to prophylaxis and targeted treatment
|
|
 |
Surgical treatment: for whom and when?
Gilbert Massard(France)
Duration:25:22
Session:Workshop 2: Lungs as target of fungi and treament
|
|
 |
In vitro susceptibility of uncommon and emerging fungal pathogens to antifungal drugs
Joseph Meletiadis(Greece)
Duration:18:34
Session:Workshop 4: Uncommon and emerging fungal pathogens
|
|
 |
The Gilead Debate: this house believes there is still a role for empirical antifungal therapy
Fransesco Menichetti(Italy)
Duration:09:44
Session:Integrated symposium 4-sponsored by Gilead
|
|
 |
Immunotherapy for Fungal Infections in the Immune - Compromised Individual: What Cells/Cytokines Should We Target?
William Murphy(USA)
Duration:22:05
Session:Plenary session 4: Host-pathogen interaction: host response
|
|
 |
The impact of PK/PD on antifungal treatment. Which drug to choose?
Andrea Novelli(Italy)
Duration:25:38
Session:Plenary session 2: The role of PK/PD in choosing antifungal drug dosing strategies
|
|
 |
Molecular typing vs traditional identification for epidemiological surveillance
Frank Odds(UK)-David Warnock(USA)
Duration:27:40
Session:Workshop 6: Molecular mycology/taxonomy
|
|
 |
Discovery and development of antifungal drugs: a reality check
Frank Odds(UK)
Duration:27:40
Session:Ben De Peauw Lecture sponsored by Gilead Sciences
|
|
 |
The Gilead Debate: this house believes there is still a role for empirical antifungal therapy
Frank Odds(UK)
Duration:14:24
Session:Integrated symposium 4-sponsored by Gilead
|
|
 |
Basic research
Nir Osherov(Israel)
Duration:32:30
Session:Workshop 13: Top ten papers: Illustrating achievements and setting new goals
|
|
 |
Cheap versus expensive antifungals
Helmut Ostermann(Germany)
Duration:18:14
Session:Workshop 14: Health economics(pros and cons)
|
|
 |
Antifungals in the pipeline
Peter G.Pappas(USA)
Duration:22:56
Session:Workshop 16: Preventing and treating IFI: What's on the horizon?
|
|
 |
ECIL vs IDSA guidelines. Trends in the management of invasive fungal infections
Peter G. Pappas(USA)
Duration:12:14
Session:Plenary session 5: Transatlantic viewpoints(us and them)
|
|
 |
Zygomycetes
George Petrikkos (Greece)
Duration:15:09
Session:Plenary session 1: Epidemiology: Do we know who gets what, why and when?
|
|
 |
Functional Genomics in Histoplasma
Chad A. Rappleye(USA)
Duration:23:07
Session:Workshop 4: Uncommon and emerging fungal pathogens
|
|
 |
The association between environment and fungal disease
Malcolm Richardson(UK)
Duration:22:24
Session:Workshop 10: Environmental mycology
|
|
 |
Neonates – approaches to prophylaxis and treatment
Emmanouel Roilides(Greece)
Duration:17:34
Session:Workshop 15: Invasive fungal infections in neonates and children
|
|
 |
Brain infection by fungi: three orders, three syndromes
Markos Ruhnke(Germany)
Duration:30:10
Session:Workshop 8: Focal fungal infections
|
|
 |
In vitro cross-resistance between azoles: a reason for concern in the clinic? - For candida
D.Sanglard(France)
Duration:20:06
Session:Workshop 11: Antifungal resistance and treatment stategies
|
|
 |
Candida affects the cytoskeleton of macrophages
Esther Segal(Israel)
Duration:18:55
Session:Plenary session 4: Host-pathogen interaction: host response
|
|
 |
Allergic bronchopulmonary aspergillosis
Ashok Shah(India)
Duration:28:37
Session:Plenary session 3: Fungi related allergic syndromes
|
|
 |
Recurrent vulvovaginal candidiasis
Jack Sobel(USA)
Duration:29:16
Session:Workshop 9: Superficial fungal infections
|
|
 |
Dermatophytosis of skin and hair in children
E.Sotiriou(Greece)
Duration:15:41
Session:Workshop 9: Superficial fungal infections
|
|
 |
The Gilead Debate: this house believes there is still a role for empirical antifungal therapy
Koen Theunissen(Belgium)
Duration:04:30
Session:Integrated symposium 4-sponsored by Gilead
|
|
 |
Diagnosis versus prophylaxis
C.Viscoli(Italy)
Duration:20:07
Session:Workshop 14: Helath economics (pros and cons)
|
|
 |
Travelling mycosis, histoplasmosis and penicilliosis
R. Wahyuningsih(Indonesia)
Duration:16:38
Session:Workshop 7: Travel and immigration related mycosis
|
|
 |
Genomic analysis during A. fumigatus infection
T.Walsh(USA)
Duration:21:47
Session:Workshop 3: Large scale analysis in the host-pathogen interaction
|
|
 |
Overview: methodology and pitfalls
D.W. Warnock(USA)
Duration:26:56
Session:Plenary session 1: Epidemiology: Do we know who gets what, why and when?
|
|
 |
Primary immunodeficiencies and fungal infections
Adilia Warris(The Netherlands)
Duration:23:05
Session:Workshop 15: Invasive fungal infections in neonates and children
|
|
 |
Epidemiology of fungal infections in pediatric hosts
Theoklis Zaoutis(USA)
Duration:21:11
Session:Workshop 15: Invasive fungal infections in neonates and children
|
|
| |
